Phathom (PHAT) Q2 Revenue Jumps 441%

Phathom Pharmaceuticals (NASDAQ:PHAT), a biopharmaceutical company specializing in treatments for gastrointestinal diseases, announced its second quarter 2025 earnings on August 7, 2025. The company's results were highlighted by a jump in GAAP revenue that surpassed analyst forecasts and robust growth in prescriptions for its lead product, VOQUEZNA, a novel acid blocker. GAAP revenue reached $39.5 million in Q2 2025, compared to consensus estimates of $36.3 million, while non-GAAP net loss narrowed to $56.5 million from $73.3 million a year earlier. Expenses showed early signs of reduction, though operating losses remain. The period reflected both strong commercial execution and the company’s efforts to streamline operations as it targets profitability in fiscal 2026. Source: Analyst estimates for the quarter provided by FactSet. Phathom Pharmaceuticals is focused on advancing treatments for acid-related gastrointestinal disorders, primarily through its lead compound, vonoprazan. Vonoprazan is a potassium-competitive acid blocker (PCAB), a newer class of drug designed to provide more rapid and lasting acid suppression than traditional proton pump inhibitors (PPIs). Unlike PPIs, vonoprazan does not require activation by stomach acid, can be taken without regard to meals.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool